Home > Treatment Options > Tumor Suppressors > Clinical Trials >


Last Updated: 03/28/17

Status: Determined Ineffective for NF2


  • Trials
  • Other Uses

Hydroxycarbamide, is no longer used or recommended for the treatment of NF2.

Other Names Hydroxyurea, Hydroxycarbamide, Hydrea, N-Hydroxyurea, Litalir, Oxyurea, Onco-carbide, Biosupressin, Droxia, Hidrix
Trade Name Hydrea™ Droxia™, Apo-Hydroxyurea™ and Gen-Hydroxyurea™,
Treatment By Pill - Oral
Inhibitor An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
Molecular Formula CH4N2O2
IUPAC hydroxyurea
ChemSpider 3530
PubChem CID 3657


  • Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent MG - www.ClinicalTrials.gov
  • Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera (PV) - www.ClinicalTrials.gov
  • Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG - www.ClinicalTrials.gov
  • Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma - www.ClinicalTrials.gov

Other Uses

  • Myeloproliferative disease
  • Sickle-cell disease
  • AIDS
  • Second line treatment for psoriasis
  • Systemic mastocytosis
  • Chronic myelogenous leukemia (replaced by imatinib
  • Biochemical research as a DNA replication inhibitor